University of Missouri School of Medicine researcher Ai-Ling Lin and colleagues report that rapamycin—a transplant-rejection drug studied for aging—raised cerebral blood flow in cognitively healthy middle-aged people carrying the Alzheimer’s-linked APOE4 variant after four weeks of low-dose treatmen